Informations générales (source: ClinicalTrials.gov)
Predictive Factors and Consequences of Myocardial Fibrosis in Hypertrophic Cardiomyopathy (HCM)
Observational
Nantes University Hospital (Voir sur ClinicalTrials)
juin 2014
décembre 2021
29 juin 2024
Fibrosis, myocardial deformation and biomarkers in hypertrophic cardiomyopathy (HCM)
Etablissements
| Les établissements hors Île-de-France dont les données sont issues de ClinicalTrials.gov Origine et niveau de fiabilité des données | |||||
|---|---|---|---|---|---|
| Nantes University Hospital - 44093 - Nantes - France | Thierry Le Tourneau, PU-PH | Contact (sur clinicalTrials) | |||
Critères
Tous
Inclusion Criteria:
- Patients with known HCM or recently discovered with a wall thickness greater than or
equal to15 mm without family background or> 13 mm in an HCM family context in the
absence of other causes found capable of producing such a degree of hypertrophy
- HCM apparently linked to a mutation of a protein of the sarcomere (identified
mutation or absence of other causes of hypertrophy found when the mutation search
was not performed or was unsuccessful)
- Control subjects will be patients greater than or equal to 18 years without known
cardiovascular disease or that may affect their ability to function, addressed to
achieve a stress echocardiography for assessment of atypical symptoms, with a low
pretest probability of coronary artery disease, and accepting blood sample before
and after exercise. They do not realize Holter ECG or cardiac MRI as part of the
study.
- Patients with known HCM or recently discovered with a wall thickness greater than or
equal to15 mm without family background or> 13 mm in an HCM family context in the
absence of other causes found capable of producing such a degree of hypertrophy
- HCM apparently linked to a mutation of a protein of the sarcomere (identified
mutation or absence of other causes of hypertrophy found when the mutation search
was not performed or was unsuccessful)
- Control subjects will be patients greater than or equal to 18 years without known
cardiovascular disease or that may affect their ability to function, addressed to
achieve a stress echocardiography for assessment of atypical symptoms, with a low
pretest probability of coronary artery disease, and accepting blood sample before
and after exercise. They do not realize Holter ECG or cardiac MRI as part of the
study.
- Refusal of the patient
- Age < 16 years old
- Valvulopathy associated significant (grade 3 or 4 regurgitation, or severe stenosis)
other than mitral insufficiency
- Defibrillator, pacemaker, or other cons-indication or intolerance to achieving MRI
- Unable to receive clear information (patient's intellectual default)
- Under protective measure of justice